2m 2m 2m 2m 2m 2m 2m
PELTHOS THERAP (PTHS)
NYSE
$25.86-$0.02 (-0.08%)
Price as of Jun 03, 2026 4:10 PM EDT- $92.0MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
PELTHOS THERAP (PTHS)
$25.86-$0.02 (-0.08%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
Income Statement | ||||
Total Operating Revenue | 16.2M N/A | N/A N/A | N/A N/A | |
Cost of Revenue | 4.0M N/A | N/A N/A | N/A N/A | |
Gross Profit | 12.2M N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 42.5M N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -1.2M +4.12% | -1.2M -54.28% | -2.6M N/A | |
Depreciation and Amortization Expense | 1.6M +20.12% | 1.3M -30.14% | 1.9M N/A | |
Total Operating Expenses | 49.2M +550.14% | 7.6M +10.33% | 6.9M N/A | |
Operating Profit | -32.4M +328.32% | -7.6M +10.33% | -6.9M N/A | |
Interest Income | 5,000 N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | -581,055 +3,943.53% | -14,370 N/A | |
Interest Income and Expense and Net | 5,000 +100.86% | -581,055 +3,943.53% | -14,370 N/A | |
Total Nonoperating Income and Expense | -18.3M +4,670.67% | -383,091 -26.12% | -518,509 N/A | |
Income before Taxes | -50.7M +569.70% | -7.6M +2.58% | -7.4M N/A | |
Income Taxes | -7.4M N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -43.3M N/A | N/A N/A | -7.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -50.7M N/A | N/A N/A | -7.4M N/A | |
Basic EPS and Net Income | -23.04 +1,511.19% | -1.43 -124.74% | 5.78 N/A | |
Diluted EPS and Net Income | -23.04 +1,511.19% | -1.43 -124.74% | 5.78 N/A | |
Basic Weighted Average Shares | 1.9M -66.27% | 5.6M +336.69% | 1.3M N/A | |
Diluted Weighted Average Shares | 1.9M -66.27% | 5.6M +336.69% | 1.3M N/A | |
Balance Sheet | ||||
Cash and Cash Equivalents | 18.0M +3,400.49% | 513,443 +432.67% | 96,391 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 18.0M +3,400.49% | 513,443 +432.67% | 96,391 N/A | |
Total Current Assets | 53.4M +3,800.98% | 1.4M +1,320.41% | 96,391 N/A | |
Accumulated Depreciation | 932,000 N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 9.6M N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 9.6M +1,178.13% | 750,000 N/A | N/A N/A | |
Total Assets | 130.4M +9,423.99% | 1.4M +1,320.41% | 96,391 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 450,000 0.00% | 450,000 N/A | |
Total Current Liabilities | 26.0M +536.58% | 4.1M -37.57% | 6.5M N/A | |
Total Long-Term Debt | 31.4M +23,742.78% | 131,868 -82.42% | 750,082 N/A | |
Total Long-Term Liabilities | 30.1M N/A | N/A N/A | N/A N/A | |
Total Liabilities | 91.5M +2,141.28% | 4.1M -37.57% | 6.5M N/A | |
Retained Earnings | -64.8M +201.72% | -21.5M +58.84% | -13.5M N/A | |
Total Stockholders Equity | 38.9M N/A | N/A N/A | -6.4M N/A | |
Total Shares Outstanding | 3.2M -47.01% | 6.1M +55.93% | 3.9M N/A | |
Cash Flow | ||||
Cash from Operating Activities | -22.6M +289.99% | -5.8M +490.45% | -981,031 N/A | |
Capital Expenditures | 99,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -5.2M N/A | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 45.3M +630.10% | 6.2M +507.38% | 1.0M N/A | |
Financials Ratio | ||||
Gross Margin | 75.39% N/A | N/A N/A | N/A N/A | |
Operating Margin | -200.11% N/A | N/A N/A | N/A N/A | |
Return on Assets | -65.75% N/A | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.05 +512.82% | 0.34 N/A | N/A N/A | |
Cash Ratio | 0.69 +450.12% | 0.13 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.81 N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.24 -43.27% | 0.43 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow